Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1416655 | 0.86 | RAB9A (0.49) | RAB9ANPC1GAAALOX15HDAC1 | |
| SCHEMBL1556345 | 0.83 | NAAA (0.54) | RAB9ANPC1GAAHDAC1HDAC6 | |
| SCHEMBL17188462 | 0.82 | RAB9A (0.58) | RAB9ANPC1GAAALOX15HDAC1 | |
| SCHEMBL6551872 | 0.82 | RAB9A (0.58) | RAB9ANPC1GAAALOX15HDAC1 | |
| SCHEMBL1416822 | 0.82 | NAAA (0.57) | RAB9ANPC1HDAC1HDAC6HDAC3 | |
| SCHEMBL4741279 | 0.81 | ASF1A (0.51) | RAB9ANPC1GAAALOX15HDAC1 | |
| SCHEMBL8457012 | 0.80 | NPC1 (0.51) | RAB9ANPC1GAAALOX15HDAC1 | |
| SCHEMBL28311338 | 0.80 | ALDH1A1 (0.57) | NPC1GAAHDAC1HDAC3HDAC2 | |
| SCHEMBL9430957 | 0.79 | HDAC1 (0.47) | RAB9ANPC1GAAHDAC1HDAC6 | |
| SCHEMBL289886 | 0.78 | NPC1 (0.57) | RAB9ANPC1GAAALOX15HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4694834-B2 | — | — | 2011-06-08 | — | — | JP | claimed |
| EP-1539700-A4 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LTD (AU) | 2006-06-28 | — | — | EP | claimed |
| JP-2006504646-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1539700-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | Prana Biotechnology Ltd (AU) | 2005-06-15 | — | — | EP | claimed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | claimed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2308828-A2 | CaSR antagonist | Japan Tobacco Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2165830-B1 | Lithographic printing plate precursor and printing method using the same | FUJIFILM CORP (JP) | 2011-03-16 | — | — | EP | disclosed |
| EP-2189439-A2 | CaSR antagonist | Japan Tobacco, Inc. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20100071574-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PRINTING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2165830-A1 | Lithographic printing plate precursor and printing method using the same | Fujifilm Corporation (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-4675397-A | MICROBIOCIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-23 | — | — | US | disclosed |
| US-4665067-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| US-4550105-A | BETA-LACTAMASE INHIBITORS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-29 | — | — | US | disclosed |
| EP-0093376-A2 | 1-Sulfo-2-azetidinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-09 | — | — | EP | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| EP-0053816-A1 | 1-Sulfo-2-oxoazetidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | RAB9A 611/4885NPC1 1388/4885GAA 2876/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | RAB9A 611/4885NPC1 1388/4885GAA 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.